Loading...
Docoh

Conmed (CNMD)

CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery, thoracic surgery, and gastroenterology.

Company profile

Ticker
CNMD
Exchange
Website
CEO
Curt Hartman
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Aspen Laboratories, Inc. • Buffalo Filter LLC • CONMED Andover Medical, Inc. • CONMED Austria GmbH • CONMED Denmark ApS • CONMED Deutschland GmbH • CONMED Endoscopic Technologies, Inc. • CONMED France SAS • CONMED Italia SrL • CONMED Linvatec Australia PTY Ltd ...
IRS number
160977505

CNMD stock data

Analyst ratings and price targets

Last 3 months

Calendar

28 Jul 22
13 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 53.15M 53.15M 53.15M 53.15M 53.15M 53.15M
Cash burn (monthly) (no burn) (no burn) 31.16M 592.5K (no burn) (no burn)
Cash used (since last report) n/a n/a 45.41M 863.41K n/a n/a
Cash remaining n/a n/a 7.74M 52.29M n/a n/a
Runway (months of cash) n/a n/a 0.2 88.3 n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
10 Aug 22 Heather L Cohen Common Stock Payment of exercise Dispose F No No 100.85 2,847 287.12K 26,778
10 Aug 22 Heather L Cohen Common Stock Option exercise Acquire M No No 32.93 5,000 164.65K 29,625
10 Aug 22 Heather L Cohen Sars (Stock Appreciation Rights) Common Stock Option exercise Dispose M No No 32.93 5,000 164.65K 5,000
30 Jun 22 Daniel Jonas Common Stock Grant Acquire A No No 90.97 22 2K 12,234
30 Jun 22 Brent Lalomia Common Stock Acquire L No No 97.693 0.737 72 678.737
30 Jun 22 Heather L Cohen Common Stock Grant Acquire A No No 90.97 1 90.97 24,625
30 Jun 22 Todd W. Garner Common Stock Grant Acquire A No No 90.97 1 90.97 1
27.7% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 275 0 NEW
Opened positions 275 0 NEW
Closed positions 0 256 EXIT
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 4.76B 0 NEW
Total shares 32.06M 0 NEW
Total puts 56.5K 0 NEW
Total calls 15.6K 0 NEW
Total put/call ratio 3.6
Largest owners Shares Value Change
BLK Blackrock 4.67M $693.84M NEW
Vanguard 3.19M $473.68M NEW
Earnest Partners 1.47M $219.06M NEW
Champlain Investment Partners 1.37M $203.96M NEW
AMP Ameriprise Financial 1.23M $182.74M NEW
Capital Research Global Investors 1.14M $169.25M NEW
STT State Street 1.04M $155.2M NEW
JPM JPMorgan Chase & Co. 836.18K $124.22M NEW
Loomis Sayles & Co L P 775K $115.13M NEW
PFG Principal Financial Group Inc - Registered Shares 729.7K $108.4M NEW
Largest transactions Shares Bought/sold Change
BLK Blackrock 4.67M +4.67M NEW
Vanguard 3.19M +3.19M NEW
Earnest Partners 1.47M +1.47M NEW
Champlain Investment Partners 1.37M +1.37M NEW
AMP Ameriprise Financial 1.23M +1.23M NEW
Capital Research Global Investors 1.14M +1.14M NEW
STT State Street 1.04M +1.04M NEW
JPM JPMorgan Chase & Co. 836.18K +836.18K NEW
Loomis Sayles & Co L P 775K +775K NEW
PFG Principal Financial Group Inc - Registered Shares 729.7K +729.7K NEW

Financial report summary

?
Risks
  • Our financial performance is dependent on conditions in the healthcare industry and the broader economy.
  • The COVID-19 global pandemic may pose significant risks to our business if the pandemic, and various responses to it, continue for an extended period of time.
  • As a manufacturer of medical devices that interacts with physicians and health care providers domestically and internationally, we face risks under domestic and foreign regulations, including the Foreign Corrupt Practices Act.
  • The highly competitive market for our products may create adverse pricing pressures.
  • Cost reduction efforts in the healthcare industry could put pressures on our prices and margins.
  • We may not be able to keep pace with technological change or to successfully develop new products with wide market acceptance, which could cause us to lose business to competitors.
  • Our variable rate indebtedness subjects us to interest rate risk, which could cause our debt service obligations to increase significantly.
  • Our interest rates may be impacted by the phase out of LIBOR.
  • The convertible notes hedge and warrant transactions that we entered into in connection with the offering of the Convertible Notes may affect the value of the Convertible Notes and our common stock.
  • We are subject to counterparty risk with respect to the convertible notes hedge transactions.
  • The terms of any future preferred equity or debt financing may give holders of any preferred securities or debt securities rights that are senior to rights of our common shareholders or impose more stringent operating restrictions on our company.
  • We could experience a failure of a key information technology system, process or site or a breach of information security, including a cybersecurity breach or failure of one or more key information technology systems, networks, processes, associated sites or service providers, and could potentially become liable for a breach of various data privacy regulations.
  • We rely on a third party to obtain, process and distribute sports medicine allograft tissue. If such tissue cannot be obtained, is not accepted by the market or is not accepted under numerous government regulations, our results of operations could be negatively impacted.
  • We distribute some products for third-party companies, and cannot ensure that our rights to distribute such third-party products will continue indefinitely.
  • If we lose our patents or they are held to be invalid, or if our products or services infringe on third party patents, we could become subject to liability and our competitive position could be harmed.
  • Damage to our physical properties as a result of windstorm, earthquake, fire or other natural or man-made disaster may cause a financial loss and a loss of customers.
  • Our new products may fail to achieve expected levels of market acceptance.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accretion, allocation, ankle, assembled, back, classified, consulting, cumulative, deductible, dismissing, elbow, entitled, evidence, exclusive, foot, half, holdback, irrevocably, judgement, life, likelihood, long, original, overwhelming, passage, plaintiff, precluded, preliminary, prepaid, prepayment, pretax, proforma, provision, reaching, recent, remeasured, remote, shareholder, strength, subsequent, Supplemental, treatment, unamortized, upper, volatility, workforce, wrist
Removed: discovery, distribution, hearing, legitimate, maintaining, oral, September, substantive, support

Patents

Utility
Multi-barrel drill guide and anchor deployment assembly
9 Aug 22
A method for suspension of the CMC joint that minimizes patient irritation/discomfort and damage to the surrounding tissue.
Utility
Electrosurgical device
9 Aug 22
Presented are an apparatus, method and electrosurgical device for surgical procedures.
Utility
Automated Anchor Insertion System
4 Aug 22
An automated anchor inserter system for drilling a pilot hole and inserting an anchor.
Utility
High Permittivity Electrosurgical Electrode Coating
4 Aug 22
A coating for the electrode of an electrosurgical instrument that increases the capacitance of the electrode.
Utility
Gas circulation system with gas sealed access cap and valve sealed access cap for robotically assisted surgical procedures
2 Aug 22
A gas circulation system is disclosed for performing robotically assisted surgical procedures in a surgical cavity of a patient, which includes a multi-lumen tube set including a dual lumen portion having a pressurized gas line and a return gas line, and a single lumen portion having a gas supply and sensing line, a valve sealed access cap for cooperative reception with a first robotic cannula and having an inlet path for communicating with the gas supply and sensing line of the tube set, and a gas sealed access cap for cooperative reception with a second robotic cannula and having an inlet path for communicating with the pressurized gas line of the tube set and an outlet path for communicating with the return gas line of the tube set.